Atrial Fibrillation (AF)
Conditions
Keywords
Atrial fibrillation, circulatory system, EKG, remote monitoring, gateway, MEMO-Patch
Brief summary
Background: Atrial fibrillation (AF) is the most common arrhythmia, significantly contributing to complications such as stroke, heart failure, dementia, and increased mortality. Catheter ablation is widely used for treatment, but recurrence rates range from 15-50% within 12 months post-procedure. Conventional intermittent ECG monitoring lacks sufficient sensitivity to detect asymptomatic AF recurrence effectively. Objective: To compare the recurrence rates of atrial tachyarrhythmias between a 1-day monitoring group and a 14-day monitoring group using MEMO Patch 2 after catheter ablation in AF patients. The study also evaluates the effectiveness and safety of early recurrence detection via remote monitoring. Study Population: Patients diagnosed with AF and treated with catheter ablation. Intervention: Participants will undergo three sessions of remote ECG monitoring using MEMO Patch 2 and MEMO Link (first session only), spanning approximately one year after catheter ablation. Hypothesis: Long-term monitoring with MEMO Patch 2 will be more effective than 1-day monitoring in detecting the recurrence of atrial tachyarrhythmias (including AF, atrial flutter, and atrial tachycardia) following catheter ablation.
Interventions
DEVICEMEMO Patch 2 - 14-day Monitoring
A wearable ECG monitoring device used for continuous 14-day monitoring to detect atrial arrhythmias during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to assess early recurrence of atrial arrhythmias.
DEVICEMEMO Patch 2 - 1-day Monitoring
A wearable ECG monitoring device used for 1-day monitoring during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to detect early recurrence of atrial arrhythmias.
DEVICEMEMO Link
A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.
Sponsors
HUINNO Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Adults aged 19 years or older who have voluntarily provided written informed consent to participate in this clinical trial. 2\. Individuals who have been diagnosed with atrial fibrillation prior to the date of informed consent acquisition. 3\. Individuals who are scheduled to undergo catheter ablation for atrial fibrillation within three months from the date of informed consent acquisition.
Exclusion criteria
* 1\. Individuals with a history of catheter ablation prior to obtaining informed consent. 2\. Individuals with sensitive skin, allergic skin conditions, skin cancer, rashes, or other dermatological disorders. 3\. Individuals with implanted cardiac devices, such as pacemakers, implantable defibrillators, or other implantable electronic devices. 4\. Individuals deemed by the investigator to be at an increased risk or otherwise unsuitable for participation in the clinical trial. 5\. Individuals with cognitive impairments that make it difficult to understand trial information or voluntarily make an informed decision. 6\. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence rate of atrial tachyarrhythmias 3 months post-catheter ablation | 3 months post-ablation | The proportion of participants with atrial tachyarrhythmias (including atrial fibrillation, atrial flutter, or atrial tachycardia lasting 30 seconds or more) detected during ECG monitoring at 3 months after catheter ablation using the MEMO Patch 2. The primary measure focuses on comparing the detection rate between the 14-day monitoring group and the 1-day monitoring group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Medical Interventions Following Catheter Ablation | 12 months post-ablation | Proportion of participants requiring additional medical interventions such as anti-arrhythmic drug cessation, repeat ablation procedures, or unplanned clinical visits post-ablation. |
| Recurrence Rate of Atrial Tachyarrhythmias at 12 Months | 12 months post-ablation | Proportion of participants experiencing atrial tachyarrhythmias (lasting 30 seconds or more) detected by MEMO Patch 2 within 12 months after catheter ablation. |
| Early Recurrence Rate of Atrial Tachyarrhythmias | 3 months post-ablation | Proportion of participants with atrial tachyarrhythmias detected within 3 months post-ablation using MEMO Patch 2. |
| Detection Rate of Non-Atrial Tachyarrhythmias Using MEMO Patch 2 | 12 months post-ablation | Proportion of participants with non-atrial tachyarrhythmias, such as ventricular premature contractions or supraventricular tachycardia, detected during MEMO Patch 2 monitoring. |
| Risk Factors for Early and Late Recurrence of Atrial Tachyarrhythmias | 12 months post-ablation | Identification of clinical risk factors associated with early recurrence (within 3 months) and late recurrence (beyond 3 months) of atrial tachyarrhythmias following catheter ablation, using data collected through MEMO Patch 2 monitoring. |
| ECG Signal Transmission Success Rate Using MEMO Link | During all monitoring periods (up to 12 months post-ablation) | Percentage of successfully transmitted ECG signals during the monitoring period using the MEMO Link device. |
| Detection Rate of Atrial Tachyarrhythmias in Daily Monitoring Reports | 30 days post-ablation (first monitoring phase) | Proportion of participants with atrial tachyarrhythmias detected using daily ECG monitoring reports during the first monitoring phase (up to 30 days post-ablation). |
| Device-Related Adverse Events | During all monitoring periods (up to 12 months post-ablation) | Rate of adverse events potentially related to the use of MEMO Patch 2 or MEMO Link during the study period, assessed through investigator reports. |
| Time to First Recurrence of Atrial Tachyarrhythmias | 12 months post-ablation | The time interval from catheter ablation to the first detection of atrial tachyarrhythmias lasting 30 seconds or more during MEMO Patch 2 monitoring. |
Countries
South Korea
Contacts
Primary ContactJong-il Choi
Outcome results
None listed